Notice to Our Users - Redesigned National Guideline Clearinghouse (NGC) Coming Soon!We are redesigning the NGC Web site for release this summer! Responsive Web Design (RWD) techniques will provide a better viewing experience across a wide range of devices, from desktop and laptop computers, to tablets and mobile phones.
|In addition to the new design, NGC will feature updated searching capabilities by using filters and facets for refining your search results, and updated browsing capabilities for the Browse by Topic and Browse by Organization pages.|
The redesigned NGC Web site will be more intuitive, with an improved, new look and feel, but will maintain the same great content that has defined NGC for many years. For a preview, visit NGC.
SAVE THE DATE for the next Guidelines International Network North America (G-I-N/NA) Webinar
- Topic: New National Guideline Clearinghouse (NGC) and National Quality Measures Clearinghouse (NQMC) Web site Debut
- Date: June 21, 2016, 4 PM EST/ 3 PM CST/ 1 PM PST
- Register in advance: https://cc.readytalk.com/
registration/#/?meeting= yx5dgg55xc71&campaign= zsdjh375fh8
- The Guidelines International Network (G-I-N) 13th annual conference will take place from September 27-30, 2016 in Philadelphia. This conference will be co-hosted by the American College of Physicians, ECRI Institute and Penn Medicine. The theme is "Individualised Guidelines and Clinical Performance Measurement in an Era of Personalised Medicine." Deadline for Early Bird Registration is June 20, 2016. For more information, visit theG-I-N Conference Web site.
U.S. Food and Drug Administration (FDA) Advisories
- June 2, 2016: Zecuity (sumatriptan) Migraine Patch: FDA is investigating the risk of serious burns and potential permanent scarring with the use of Zecuity (sumatriptan iontophoretic transdermal system) patch for migraine headaches. Since marketing of the Zecuity patch began in September 2015, a large number of patients have reported they experienced burns or scars on the skin where the patch was worn. The reports included descriptions of severe redness, pain, skin discoloration, blistering, and cracked skin. As a result, FDA is investigating these serious adverse events to determine whether future regulatory action is needed, and will update the public with new information when the FDA review is complete.
- June 6, 2016: Over-the-Counter Antacid Products Containing Aspirin: The FDA is warning consumers about the risk of serious bleeding when using nonprescription, also known as over-the-counter or OTC, aspirin-containing antacid products to treat heartburn, sour stomach, acid indigestion, or upset stomach. Many other products for these conditions are available that do not contain aspirin.
- June 7, 2016: Loperamide (Imodium): FDA is warning that taking higher than recommended doses of the common over-the-counter (OTC) and prescription diarrhea medicine loperamide (Imodium), including through abuse or misuse of the product, can cause serious heart problems that can lead to death. The risk of these serious heart problems, including abnormal heart rhythms, may also be increased when high doses of loperamide are taken with several kinds of medicines that interact with loperamide (see Examples of Drugs that Can Potentially Interact with Loperamide, in the FDA Drug Safety Communication).